Weight Management Opportunity Novo Nordisk is a leading player in obesity and weight-management therapies with Ozempic and Wegovy driving a large portion of revenue. This indicates strong market traction and potential demand for complementary digital health, patient support programs, and personalized adherence solutions that can pair with their GLP-1–based portfolio.
Biopharma Partnerships The company collaborates across health initiatives and markets, expanding through partnerships and media/advertising activities. This presents opportunities to offer integrated marketing technology, programmatic analytics, and omnichannel campaigns to optimize reach and engagement with clinicians and patients.
Regulatory & Compliance Edge Operating in a highly regulated environment with frequent regulatory considerations, Novo Nordisk could benefit from compliance-focused tech and services such as governance, risk, and privacy management; audit-ready reporting; and secure data platforms that streamline regulatory submissions and pharmacovigilance.
Global Scale With 66,700 employees across 80 offices, there is a need for scalable enterprise solutions in data analytics, cloud governance, and security; opportunities exist to offer enterprise tooling, regional data pipelines, and collaboration platforms that support global operations and cross-border data flows.
Competitive Momentum Rising competition in obesity and anti-obesity markets alongside legal challenges around insulin pricing signals a need for competitive intelligence, pricing analytics, payer strategy, and market access solutions to sustain growth and differentiate in complex markets.